Home / Business and Economy / Laurus Labs Hits Record Revenue, Stock Soars 55%
Laurus Labs Hits Record Revenue, Stock Soars 55%
27 Jul
Summary
- Laurus Labs achieved record quarterly revenue of ₹2,026 crore.
- EBITDA grew 66% to ₹644 crore with improved margins.
- Brokerages maintain 'BUY' ratings with target prices up to ₹1,980.
Laurus Labs' share price surged to a new record of ₹1,662.45, marking a 55% increase in five months. This rise follows the company's delivery of a record quarterly revenue of ₹2,026 crore for Q1FY27, representing a 29% growth.
Operating performance remained strong despite market volatility, with EBITDA reaching ₹644 crore, a 66% increase year-on-year. EBITDA margins improved to 31.8% due to enhanced capacity utilization and operating leverage.
The company is strategically expanding its portfolio, including in-licensing two Antibody Drug Conjugates (ADCs). Management anticipates sustained momentum across its CDMO and Affordable Medicines divisions.
Brokerages like Motilal Oswal and ICICI Securities have reiterated 'BUY' ratings, with target prices of ₹1,980 and ₹1,890 respectively. These positive outlooks are based on projected earnings growth and significant investments in manufacturing and technology.
